• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Jupiter Neurosciences Inc.

    8/14/25 4:48:23 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    OMB APPROVAL
    OMB Number: 3235-0058
    Expires: August 31, 2025
    Estimated average burden hours per response ... 2.50
     
    SEC FILE NUMBER
    001-41265
     

    CUSIP NUMBER

    48208B203

     

    (Check one):   ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

     

        For Period Ended: June 30, 2025
         
        ☐ Transition Report on Form 10-K
         
        ☐ Transition Report on Form 20-F
         
        ☐ Transition Report on Form 11-K
         
        ☐ Transition Report on Form 10-Q
         
        ☐ Transition Report on Form N-SAR
         
        For the Transition Period Ended:

     

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Jupiter Neurosciences, Inc.
    Full Name of Registrant

     

     
    Former Name if Applicable

     

    1001 North US HWY 1, Suite 504
    Address of Principal Executive Office (Street and Number)

     

    Jupiter, FL 33477
    City, State and Zip Code

     

     

     

     
     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
       
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
       
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    JUPITER NEUROSCIENCES, INC. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Form 10-Q”) within the prescribed time period applicable to smaller reporting companies because it requires additional time to complete the presentation and review of its financial statements and related disclosures. The Registrant anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Christer Rosén   (561)   406-6154
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes ☒ No ☐
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes ☐ No ☒
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     
     

     

    JUPITER NEUROSCIENCES, INC.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    August 14, 2025 By: /s/ Christer Rosén
      Name: Christer Rosén
      Title: Chief Executive Officer

     

     

     

    Get the next $JUNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pres + Chief Business Officer Silva Alison D.

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/7/25 9:28:07 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Secretary Elmasri Saleem converted options into 66,293 shares (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/7/25 9:28:09 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

    Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line. This initiative reinforces Jupiter's dual-engine strategy, combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As GLP-1 adoption accelerates globally, Jupiter se

    1/28/26 6:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6

    Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences' scientific platform, clinical development plans, and commercial strategy heading into 2026. Rosén will discuss the Company's lead asset, JOTROL™, including its differentiated bioavailability profile and upcom

    12/23/25 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

    Company advances JOTROL™ into Phase 2a Parkinson's trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter's first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026. Dear Fellow Shareholders, As we celebrate our first full year as a public company, I want to express m

    12/3/25 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    SEC Filings

    View All

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    12/23/25 5:29:33 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    12/22/25 4:30:30 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Jupiter Neurosciences Inc.

    424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    12/19/25 5:30:15 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 8:56:52 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/3/25 2:53:00 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/1/25 7:55:51 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care